BACKGROUND: We have a limited understanding of the biological underpinnings of symptoms in heart failure (HF), particularly in response to left ventricular assist device (LVAD) implantation. OBJECTIVE: The aim of this study was to quantify the degree to which symptoms and biomarkers change in parallel from before implantation through the first 6 months after LVAD implantation in advanced HF. METHODS: This was a prospective cohort study of 101 patients receiving an LVAD for the management of advanced HF. Data on symptoms (dyspnea, early and subtle symptoms [HF Somatic Perception Scale], pain severity [Brief Pain Inventory], wake disturbance [Epworth Sleepiness Scale], depression [Patient Health Questionnaire], and anxiety [Brief Symptom Inve...
Heart failure is a global and growing problem that affects 1-2% of people. For patients with end-sta...
Background: Left ventricular assist device (LVAD) therapy is increasingly used in patients with adv...
Aims: Sympathetic overactivity, which predicts poor outcome in patients with heart failure, normaliz...
BACKGROUND: We have a limited understanding of the biological underpinnings of symptoms in heart fai...
Background: We have a limited understanding of the biological underpinnings of symptoms in heart fa...
Background: Although we know that the quality of life generally improves after left ventricular ass...
Background: Unexplained heterogeneity in response to ventricular assist device (VAD) implantation f...
Background: Advanced heart failure patients who face end-of-life may require a left ventricular ass...
Aims Left ventricular assist devices (LVAD) are used to treat advanced heart failure, and the use of...
Patients with a left ventricular assist device (LVAD) commonly experience psychological distress pos...
Background Clinical response to left ventricular assist devices (LVADs), as measured by health-rela...
AIMS: Despite well-known gender differences in heart failure, it is unknown if clinical markers and ...
Aims Despite well-known gender differences in heart failure, it is unknown if clinical markers and s...
Background Improving patient-reported outcomes (e.g. health status) has become an important goal in ...
Background: Left ventricular assist devices (LVADs) reduce pulmonary vascular resistance (PVR) in pa...
Heart failure is a global and growing problem that affects 1-2% of people. For patients with end-sta...
Background: Left ventricular assist device (LVAD) therapy is increasingly used in patients with adv...
Aims: Sympathetic overactivity, which predicts poor outcome in patients with heart failure, normaliz...
BACKGROUND: We have a limited understanding of the biological underpinnings of symptoms in heart fai...
Background: We have a limited understanding of the biological underpinnings of symptoms in heart fa...
Background: Although we know that the quality of life generally improves after left ventricular ass...
Background: Unexplained heterogeneity in response to ventricular assist device (VAD) implantation f...
Background: Advanced heart failure patients who face end-of-life may require a left ventricular ass...
Aims Left ventricular assist devices (LVAD) are used to treat advanced heart failure, and the use of...
Patients with a left ventricular assist device (LVAD) commonly experience psychological distress pos...
Background Clinical response to left ventricular assist devices (LVADs), as measured by health-rela...
AIMS: Despite well-known gender differences in heart failure, it is unknown if clinical markers and ...
Aims Despite well-known gender differences in heart failure, it is unknown if clinical markers and s...
Background Improving patient-reported outcomes (e.g. health status) has become an important goal in ...
Background: Left ventricular assist devices (LVADs) reduce pulmonary vascular resistance (PVR) in pa...
Heart failure is a global and growing problem that affects 1-2% of people. For patients with end-sta...
Background: Left ventricular assist device (LVAD) therapy is increasingly used in patients with adv...
Aims: Sympathetic overactivity, which predicts poor outcome in patients with heart failure, normaliz...